Europe s drug makers have warned they may stop making some cheap generic medicines because of surging electricity costs and are calling for an overhaul of the way they are priced, the latest industry to seek help as the energy crisis deepens.
Europe s drug makers have warned they may stop making some cheap generic medicines because of surging electricity costs and are calling for an overhaul of the way they are priced, the latest industry to seek help as the energy crisis deepens.
/PRNewswire/ Research Dive in its latest published report estimates that the global biosimilar market will generate $83,836.40 million and exhibit a CAGR of.